Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized Controlled, Multicenter Study With Dual HRD-positive/Negative Cohorts Evaluating Fluzoparib Monotherapy Versus Combination Therapy With Bevacizumab or Dietary Intervention as Maintenance Treatment Following First-line Platinum-based Chemotherapy in Advanced Ovarian Cancer

NCT06954584 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT06954584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06954584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized Controlled, Multicenter Study With Dual HRD-positive/Negative Cohorts Evaluating Fluzoparib Monotherapy Versus Combination Therapy With Bevacizumab or Dietary Intervention as Maintenance Treatment Following First-line Platinum-based Chemotherapy in Advanced Ovarian Cancer
Lead sponsor
Tongji Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
May 27, 2025
Completion date
March 1, 2032
Enrollment
424 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer